1
|
Jakovljevic A, Knezevic A, Nikolic N, Soldatovic I, Jovanovic T, Milasin J, Andric M. Herpesviruses viral loads and levels of proinflammatory cytokines in apical periodontitis. Oral Dis 2018; 24:840-846. [DOI: 10.1111/odi.12829] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Revised: 01/01/2018] [Accepted: 01/03/2018] [Indexed: 12/19/2022]
Affiliation(s)
- A Jakovljevic
- Department of Pathophysiology; School of Dental Medicine; University of Belgrade; Belgrade Serbia
| | - A Knezevic
- Department of Virology; Institute of Microbiology and Immunology; Faculty of Medicine; University of Belgrade; Belgrade Serbia
| | - N Nikolic
- Department of Human Genetics; School of Dental Medicine; University of Belgrade; Belgrade Serbia
| | - I Soldatovic
- Department of Medical Statistics and Informatics; Faculty of Medicine; University of Belgrade; Belgrade Serbia
| | - T Jovanovic
- Department of Virology; Institute of Microbiology and Immunology; Faculty of Medicine; University of Belgrade; Belgrade Serbia
| | - J Milasin
- Department of Human Genetics; School of Dental Medicine; University of Belgrade; Belgrade Serbia
| | - M Andric
- Clinic of Oral Surgery; School of Dental Medicine; University of Belgrade; Belgrade Serbia
| |
Collapse
|
2
|
Jakovljevic A, Andric M, Nikolic N, Coric V, Krezovic S, Carkic J, Knezevic A, Beljic-Ivanovic K, Pljesa-Ercegovac M, Miletic M, Soldatovic I, Radosavljevic T, Jovanovic T, Simic T, Ivanovic V, Milasin J. Levels of oxidative stress biomarkers and bone resorption regulators in apical periodontitis lesions infected by Epstein-Barr virus. Int Endod J 2018; 51:593-604. [PMID: 29315650 DOI: 10.1111/iej.12886] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Accepted: 01/04/2018] [Indexed: 02/05/2023]
Abstract
AIM To investigate whether apical periodontitis lesions infected by Epstein-Barr virus (EBV) exhibit higher levels of oxidative stress biomarkers [8-hydroxydeoxyguanosine (8-OHdG) and oxidized glutathione (GSSG)] and bone resorption regulators [receptor activator of nuclear factor (NF-κB) ligand (RANKL) and osteoprotegerin (OPG)] compared to EBV-negative periapical lesions and healthy pulp tissues. METHODOLOGY The experimental group consisted of 30 EBV-positive and 30 EBV-negative periapical lesions collected in conjunction with apicoectomy. The pulp tissues of 20 impacted third molars were used as healthy controls. The qualitative and quantitative analysis of EBV was performed by nested and real-time polymerase chain reaction (PCR), respectively. The levels of RANKL and OPG were analysed by reverse transcriptase real-time PCR. The levels of 8-OHdG and GSSG were determined by enzyme-linked immunosorbent assay (ELISA). Mann-Whitney U-test and Spearman's correlation were used for statistical analysis. RESULTS The levels of RANKL, OPG, 8-OHdG and GSSG were significantly higher in apical periodontitis lesions compared to healthy pulp controls (P = 0.001, P < 0.001, P < 0.001 and P < 0.05, respectively). RANKL and OPG mRNA expression was significantly higher in EBV-positive compared to EBV-negative periapical lesions (P < 0.05). There was no significant correlation between EBV copy numbers and levels of RANKL, OPG, 8OH-dG and GSSG in apical periodontitis. CONCLUSION Levels of bone resorption regulators and oxidative stress biomarkers were increased in apical periodontitis compared to healthy pulp tissues. EBV-positive periapical lesions exhibited higher levels of RANKL and OPG compared to EBV-negative periapical lesions. EBV may contribute to progression of apical periodontitis via enhanced production of bone resorption regulators.
Collapse
Affiliation(s)
- A Jakovljevic
- Department of Pathophysiology, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.,Clinic of Oral Surgery, School of Dental Medicine, University of Belgrade, Belgrade, Serbia
| | - M Andric
- Clinic of Oral Surgery, School of Dental Medicine, University of Belgrade, Belgrade, Serbia
| | - N Nikolic
- Department of Biology and Human Genetics, School of Dental Medicine, University of Belgrade, Belgrade, Serbia
| | - V Coric
- Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - S Krezovic
- Clinic of Oral Surgery, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.,Department of Biology and Human Genetics, School of Dental Medicine, University of Belgrade, Belgrade, Serbia
| | - J Carkic
- Department of Biology and Human Genetics, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.,Department of Microbiology, School of Dental Medicine, University of Belgrade, Belgrade, Serbia
| | - A Knezevic
- Institute of Microbiology and Immunology, Department of Virology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - K Beljic-Ivanovic
- Clinic of Restorative Dentistry and Endodontics, School of Dental Medicine, University of Belgrade, Belgrade, Serbia
| | - M Pljesa-Ercegovac
- Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - M Miletic
- Department of Pathophysiology, School of Dental Medicine, University of Belgrade, Belgrade, Serbia
| | - I Soldatovic
- Institute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - T Radosavljevic
- Institute of Pathophysiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - T Jovanovic
- Institute of Microbiology and Immunology, Department of Virology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - T Simic
- Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - V Ivanovic
- Clinic of Restorative Dentistry and Endodontics, School of Dental Medicine, University of Belgrade, Belgrade, Serbia
| | - J Milasin
- Department of Biology and Human Genetics, School of Dental Medicine, University of Belgrade, Belgrade, Serbia
| |
Collapse
|
3
|
Viral surveillance and subclinical viral infection in pediatric kidney transplantation. Pediatr Nephrol 2015; 30:741-8. [PMID: 25125226 PMCID: PMC6192669 DOI: 10.1007/s00467-014-2866-8] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2014] [Revised: 05/19/2014] [Accepted: 05/21/2014] [Indexed: 12/20/2022]
Abstract
The more potent immunosuppressive therapy that has successfully reduced the incidence of acute rejection and improved graft outcomes has also resulted in a higher incidence of viral complications. Sensitive molecular methods now allow for the detection of subclinical viral infection, which is increasingly recognized due to the adoption of routine post-transplant viral surveillance protocols. The goal of viral surveillance is the detection of subclinical viral infection that triggers an intervention; one that either prevents progression to viral disease or leads to early diagnosis of viral disease, which is associated with improved outcomes. Knowledge of the epidemiology and natural history of subclinical viral infection and viral disease, as well as patient-specific risk factors, is required to establish the optimal surveillance schedule which achieves the goal of early diagnosis. Evidence that detection of subclinical viral infection can impact viral disease is variable depending on the virus. This review will summarize the current data on the role of viral surveillance for BK virus (BKV), cytomegalovirus (CMV), and the Epstein-Barr virus (EBV) in the pediatric kidney transplant population.
Collapse
|
4
|
Fellner MD, Durand K, Rodriguez M, Irazu L, Alonio V, Picconi MA. Duplex realtime PCR method for Epstein-Barr virus and human DNA quantification: its application for post-transplant lymphoproliferative disorders detection. Braz J Infect Dis 2014; 18:271-80. [PMID: 24389276 PMCID: PMC9427524 DOI: 10.1016/j.bjid.2013.07.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2013] [Accepted: 07/16/2013] [Indexed: 12/12/2022] Open
Abstract
INTRODUCTION The quantification of circulating Epstein-Barr virus (EBV) DNA is used to monitor transplant patients as an early marker of Post-Transplant Lymphoproliferative Disorders (PTLD). So far no standardized methodology exists for such determination. OBJECTIVE Our purpose was to develop and validate a real-time PCR assay to quantify EBV DNA in clinical samples from transplant recipients. METHODS A duplex real-time PCR method was developed to amplify DNA from EBV and from a human gene. The EBV load was determined in peripheral blood mononuclear cells (PBMC), plasma and oropharyngeal tissue from 64 non-transplanted patients with lymphoid-hypertrophy (Non-Tx), 47 transplant recipients without PTLD (Tx), 54 recipients with PTLD (Tx-PTLD), and 66 blood donors (BD). WinPEPI, version 11.14 software was used for statistical analysis. RESULTS Analytical validation: the intra and inter-assays variation coefficients were less than 4.5% (EBV-reaction) and 3% (glyceraldehyde 3-phosphate dehydrogenase - GAPDH reaction). Linear ranges comprised 10(7)-10 EBV genome equivalents (gEq) (EBV-reaction) and 500,000-32 human gEq (GAPDH-reaction). The detection limit was 2.9 EBV gEq (EBV-reaction). Both reactions showed specificity. Application to clinical samples: higher levels of EBV were found in oropharyngeal tissue from transplanted groups with and without PTLD, compared to Non-Tx (p<0.05). The EBV load in PBMC from the groups of BD, Non-Tx, Tx and Tx-PTLD exhibited increasing levels (p<0.05). In BD, PBMC and plasma, EBV loads were undetectable. CONCLUSIONS The performance of the assay was suitable for the required clinical application. The assay may be useful to monitor EBV infection in transplant patients, in particular in laboratories from low-income regions that cannot afford to use commercial assays.
Collapse
Affiliation(s)
- María Dolores Fellner
- Oncogenic Viruses Service, Virology Department, National Institute of Infectious Diseases "Carlos G. Malbrán", Av. Vélez Sársfield 563, C1282AFF Buenos Aires, Argentina.
| | - Karina Durand
- Oncogenic Viruses Service, Virology Department, National Institute of Infectious Diseases "Carlos G. Malbrán", Av. Vélez Sársfield 563, C1282AFF Buenos Aires, Argentina
| | - Marcelo Rodriguez
- Operational Team Quality Management, Parasitology Department, National Institute of Infectious Diseases "Carlos G. Malbrán", Av. Vélez Sársfield 563, C1282AFF Buenos Aires, Argentina
| | - Lucía Irazu
- Operational Team Quality Management, Parasitology Department, National Institute of Infectious Diseases "Carlos G. Malbrán", Av. Vélez Sársfield 563, C1282AFF Buenos Aires, Argentina
| | - Virginia Alonio
- Oncogenic Viruses Service, Virology Department, National Institute of Infectious Diseases "Carlos G. Malbrán", Av. Vélez Sársfield 563, C1282AFF Buenos Aires, Argentina
| | - María Alejandra Picconi
- Oncogenic Viruses Service, Virology Department, National Institute of Infectious Diseases "Carlos G. Malbrán", Av. Vélez Sársfield 563, C1282AFF Buenos Aires, Argentina
| |
Collapse
|
5
|
Hu C, Wei W, Chen X, Woodman CB, Yao Y, Nicholls JM, Joab I, Sihota SK, Shao JY, Derkaoui KD, Amari A, Maloney SL, Bell AI, Murray PG, Dawson CW, Young LS, Arrand JR. A global view of the oncogenic landscape in nasopharyngeal carcinoma: an integrated analysis at the genetic and expression levels. PLoS One 2012; 7:e41055. [PMID: 22815911 PMCID: PMC3398876 DOI: 10.1371/journal.pone.0041055] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2012] [Accepted: 06/17/2012] [Indexed: 12/22/2022] Open
Abstract
Previous studies have reported that the tumour cells of nasopharyngeal carcinoma (NPC) exhibit recurrent chromosome abnormalities. These genetic changes are broadly assumed to lead to changes in gene expression which are important for the pathogenesis of this tumour. However, this assumption has yet to be formally tested at a global level. Therefore a genome wide analysis of chromosome copy number and gene expression was performed in tumour cells micro-dissected from the same NPC biopsies. Cellular tumour suppressor and tumour-promoting genes (TSG, TPG) and Epstein-Barr Virus (EBV)-encoded oncogenes were examined. The EBV-encoded genome maintenance protein EBNA1, along with the putative oncogenes LMP1, LMP2 and BARF1 were expressed in the majority of NPCs that were analysed. Significant downregulation of expression in an average of 76 cellular TSGs per tumour was found, whilst a per-tumour average of 88 significantly upregulated, TPGs occurred. The expression of around 60% of putative TPGs and TSGs was both up-and down-regulated in different types of cancer, suggesting that the simplistic classification of genes as TSGs or TPGs may not be entirely appropriate and that the concept of context-dependent onco-suppressors may be more extensive than previously recognised. No significant enrichment of TPGs within regions of frequent genomic gain was seen but TSGs were significantly enriched within regions of frequent genomic loss. It is suggested that loss of the FHIT gene may be a driver of NPC tumourigenesis. Notwithstanding the association of TSGs with regions of genomic loss, on a gene by gene basis and excepting homozygous deletions and high-level amplification, there is very little correlation between chromosomal copy number aberrations and expression levels of TSGs and TPGs in NPC.
Collapse
Affiliation(s)
- Chunfang Hu
- School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
| | - Wenbin Wei
- School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
| | - Xiaoyi Chen
- School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
- Department of Pathology, Guangdong Medical College, Zhanjiang, Guangdong, China
| | - Ciaran B. Woodman
- School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
| | - Yunhong Yao
- School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
- Department of Pathology, Guangdong Medical College, Zhanjiang, Guangdong, China
| | - John M. Nicholls
- Department of Pathology, University of Hong Kong, Hong Kong, China
| | - Irène Joab
- UMR542 Inserm-Université Paris Sud, Villejuif, France
| | - Sim K. Sihota
- School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
| | - Jian-Yong Shao
- Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Centre, Guangzhou, China
| | - K. Dalia Derkaoui
- Laboratoire de Biologie du Développement et de la Différenciation, Faculté des Sciences, Université d’Oran, Oran, Algeria
| | - Aicha Amari
- ORL Centre Hospitalier et Universitaire, Oran, Algeria
| | | | - Andrew I. Bell
- School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
| | - Paul G. Murray
- School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
| | | | - Lawrence S. Young
- School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
| | - John R. Arrand
- School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
- * E-mail:
| |
Collapse
|
6
|
Mengelle C, Kamar N, Mansuy JM, Sandres-Sauné K, Legrand-Abravanel F, Miédougé M, Rostaing L, Izopet J. JC virus DNA in the peripheral blood of renal transplant patients: A 1-year prospective follow-up in France. J Med Virol 2010; 83:132-6. [DOI: 10.1002/jmv.21951] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
7
|
Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 2010; 23:350-66. [PMID: 20375356 DOI: 10.1128/cmr.00006-09] [Citation(s) in RCA: 158] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Epstein-Barr virus (EBV) DNA measurement is being incorporated into routine medical practice to help diagnose, monitor, and predict posttransplant lymphoproliferative disorder (PTLD) in immunocompromised graft recipients. PTLD is an aggressive neoplasm that almost always harbors EBV DNA within the neoplastic lymphocytes, and it is often fatal if not recognized and treated promptly. Validated protocols, commercial reagents, and automated instruments facilitate implementation of EBV load assays by real-time PCR. When applied to either whole blood or plasma, EBV DNA levels reflect clinical status with respect to EBV-related neoplasia. While many healthy transplant recipients have low viral loads, high EBV loads are strongly associated with current or impending PTLD. Complementary laboratory assays as well as histopathologic examination of lesional tissue help in interpreting modest elevations in viral load. Circulating EBV levels in serial samples reflect changes in tumor burden and represent an effective, noninvasive tool for monitoring the efficacy of therapy. In high-risk patients, serial testing permits early clinical intervention to prevent progression toward frank PTLD. Restoring T cell immunity against EBV is a major strategy for overcoming PTLD, and novel EBV-directed therapies are being explored to thwart virus-driven neoplasia.
Collapse
|
8
|
|
9
|
Comparison of two highly automated DNA extraction systems for quantifying Epstein–Barr virus in whole blood. J Clin Virol 2008; 43:272-6. [DOI: 10.1016/j.jcv.2008.08.005] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2008] [Revised: 08/06/2008] [Accepted: 08/11/2008] [Indexed: 11/19/2022]
|
10
|
Abstract
Epstein-Barr virus (EBV) infects various cell types in a wide spectrum of benign and malignant diseases. Laboratory tests for EBV have improved and are increasingly used in diagnosis, prognosis, prediction, and prevention of diseases ranging from infectious mononucleosis to selected subtypes of lymphoma, sarcoma, and carcinoma. Indeed, the presence of EBV is among the most effective tumor markers supporting clinical management of cancer patients. In biopsies, localization of EBER transcripts by in situ hybridization remains the gold standard for identifying latent infection. Other RNA- and protein-based assays detect lytic viral replication and can distinguish carcinoma-derived from lymphocyte-derived EBV in saliva or nasopharyngeal brushings. Analysis of blood using EBV viral load and serology reflects disease status and risk of progression. This review summarizes prior research in the context of basic virologic principles to provide a rational strategy for applying and interpreting EBV tests in various clinical settings. Such assays have been incorporated into standard clinical practice in selected settings such as diagnosis of primary infection and management of patients with immune dysfunction or nasopharyngeal carcinoma. As novel therapies are developed that target virus-infected cells or overcome the adverse effects of infection, laboratory testing becomes even more critical for determining when intervention is appropriate and the extent to which it has succeeded.
Collapse
Affiliation(s)
- Margaret L Gulley
- Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599-7525, USA.
| | | |
Collapse
|
11
|
Fafi-Kremer S, Morand P, Barranger C, Barguès G, Magro S, Bés J, Bourgeois P, Joannes M, Seigneurin JM. Evaluation of the Epstein-Barr virus R-gene quantification kit in whole blood with different extraction methods and PCR platforms. J Mol Diagn 2007; 10:78-84. [PMID: 18165270 DOI: 10.2353/jmoldx.2008.070054] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Reliable real-time quantitative PCR assays to measure Epstein-Barr virus (EBV) DNA load (EBV) are useful for monitoring EBV-associated diseases. We evaluated a new commercial kit, EBV R-gene Quantification kit (Argene, Varilhes, France) to quantify EBV DNA load in whole blood. Assay performance was assessed with two PCR platforms (LightCycler 2.0 and SmartCycler 2.0) and three commercial DNA extraction methods. The assay was compared with our in-house real-time EBV PCR using samples from the Quality Control for Molecular Diagnostics 2006 EBV proficiency program and using 167 whole-blood specimens from individuals with infectious mononucleosis, from transplanted or HIV-infected patients, and from EBV-seropositive healthy carriers. The EBV R-gene assay was sensitive to 500 copies of EBV DNA per milliliter of whole blood with the two PCR platforms and the three extraction methods and was linear across 4 orders of magnitude. Intra- and interassay coefficients of variations were less than 20%. Nine of 10 samples tested with the EBV R-gene were in agreement with the expected qualitative results of the Quality Control for Molecular Diagnostics 2006 EBV proficiency program, and 7 of 10 samples were within +/-0.5 log units of the expected quantitative values, with discrepant results mostly observed for low viral load (ie, <1000 copies/ml). In the clinical specimens, the correlation between the R-gene assay and the in-house PCR was high (r=0.92). In conclusion, the EBV R-gene assay accurately assesses the EBV DNA load in whole blood of patients with various forms of EBV infections.
Collapse
Affiliation(s)
- Samira Fafi-Kremer
- Laboratoire de Virologie Médicale, Centre Hospitalier Universitaire, Université Joseph Fourier, Grenoble, France
| | | | | | | | | | | | | | | | | |
Collapse
|